#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3 .
1-1	0-1	3	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=TRP Channels in Colorectal Cancers
2-1	4-7	TRP	abstract|abstract[3]	new|new[3]	coref|coref	6-16|6-16
2-2	8-16	Channels	abstract[3]	new[3]	_	_
2-3	17-19	in	abstract[3]	new[3]	_	_
2-4	20-30	Colorectal	abstract[3]|place|abstract[5]	new[3]|new|new[5]	coref|coref|coref|coref	3-1|8-19[57_5]|3-1|8-19[57_5]
2-5	31-38	Cancers	abstract[3]|abstract[5]	new[3]|new[5]	_	_

#Text=Colorectal cancer ( CRC ) , the most prevalent cancer of the GI tract , represents the third most commonly diagnosed malignancy worldwide in men and women and the second largest cause of death in Europe related to cancer .
3-1	39-49	Colorectal	place|abstract[7]	giv|new[7]	appos|appos	3-4[0_7]|3-4[0_7]
3-2	50-56	cancer	abstract[7]	new[7]	_	_
3-3	57-58	(	_	_	_	_
3-4	59-62	CRC	abstract	giv	appos	3-7[9_0]
3-5	63-64	)	_	_	_	_
3-6	65-66	,	_	_	_	_
3-7	67-70	the	abstract[9]	giv[9]	coref	3-39[0_9]
3-8	71-75	most	abstract[9]	giv[9]	_	_
3-9	76-85	prevalent	abstract[9]	giv[9]	_	_
3-10	86-92	cancer	abstract[9]	giv[9]	_	_
3-11	93-95	of	abstract[9]	giv[9]	_	_
3-12	96-99	the	abstract[9]|place[11]	giv[9]|new[11]	_	_
3-13	100-102	GI	abstract[9]|abstract|place[11]	giv[9]|new|new[11]	_	_
3-14	103-108	tract	abstract[9]|place[11]	giv[9]|new[11]	_	_
3-15	109-110	,	_	_	_	_
3-16	111-121	represents	_	_	_	_
3-17	122-125	the	abstract[13]	new[13]	_	_
3-18	126-131	third	abstract[13]	new[13]	_	_
3-19	132-136	most	abstract[13]	new[13]	_	_
3-20	137-145	commonly	abstract[13]	new[13]	_	_
3-21	146-155	diagnosed	abstract[13]	new[13]	_	_
3-22	156-166	malignancy	abstract|abstract[13]	new|new[13]	_	_
3-23	167-176	worldwide	abstract[13]	new[13]	_	_
3-24	177-179	in	abstract[13]	new[13]	_	_
3-25	180-183	men	abstract[13]|person	new[13]|new	_	_
3-26	184-187	and	abstract[13]	new[13]	_	_
3-27	188-193	women	abstract[13]|person	new[13]|new	_	_
3-28	194-197	and	_	_	_	_
3-29	198-201	the	abstract[16]	new[16]	_	_
3-30	202-208	second	abstract[16]	new[16]	_	_
3-31	209-216	largest	abstract[16]	new[16]	_	_
3-32	217-222	cause	abstract[16]	new[16]	_	_
3-33	223-225	of	abstract[16]	new[16]	_	_
3-34	226-231	death	abstract[16]|person[17]	new[16]|new[17]	coref	9-36[79_17]
3-35	232-234	in	abstract[16]|person[17]	new[16]|new[17]	_	_
3-36	235-241	Europe	abstract[16]|person[17]|place	new[16]|new[17]|new	_	_
3-37	242-249	related	_	_	_	_
3-38	250-252	to	_	_	_	_
3-39	253-259	cancer	abstract	giv	coref	4-19
3-40	260-261	.	_	_	_	_

#Text=Growth factors , oncogenes and receptors play a critical role in the tumorigenesis , and the propagation of CRC .
4-1	262-268	Growth	person|abstract[21]	new|new[21]	coref|coref	5-3[28_21]|5-3[28_21]
4-2	269-276	factors	abstract[21]	new[21]	_	_
4-3	277-278	,	_	_	_	_
4-4	279-288	oncogenes	substance	new	_	_
4-5	289-292	and	_	_	_	_
4-6	293-302	receptors	substance	new	_	_
4-7	303-307	play	_	_	_	_
4-8	308-309	a	abstract[24]	new[24]	coref	8-23[58_24]
4-9	310-318	critical	abstract[24]	new[24]	_	_
4-10	319-323	role	abstract[24]	new[24]	_	_
4-11	324-326	in	abstract[24]	new[24]	_	_
4-12	327-330	the	abstract[24]|event[25]	new[24]|new[25]	coref	12-11[94_25]
4-13	331-344	tumorigenesis	abstract[24]|event[25]	new[24]|new[25]	_	_
4-14	345-346	,	_	_	_	_
4-15	347-350	and	_	_	_	_
4-16	351-354	the	abstract[26]	new[26]	_	_
4-17	355-366	propagation	abstract[26]	new[26]	_	_
4-18	367-369	of	abstract[26]	new[26]	_	_
4-19	370-373	CRC	abstract[26]|abstract	new[26]|giv	coref	5-15
4-20	374-375	.	_	_	_	_

#Text=However , other environmental and genetic factors play significant roles in the development of CRC .
5-1	376-383	However	_	_	_	_
5-2	384-385	,	_	_	_	_
5-3	386-391	other	abstract[28]	giv[28]	_	_
5-4	392-405	environmental	abstract[28]	giv[28]	_	_
5-5	406-409	and	abstract[28]	giv[28]	_	_
5-6	410-417	genetic	abstract[28]	giv[28]	_	_
5-7	418-425	factors	abstract[28]	giv[28]	_	_
5-8	426-430	play	_	_	_	_
5-9	431-442	significant	abstract[29]	new[29]	_	_
5-10	443-448	roles	abstract[29]	new[29]	_	_
5-11	449-451	in	abstract[29]	new[29]	_	_
5-12	452-455	the	abstract[29]|abstract[30]	new[29]|new[30]	_	_
5-13	456-467	development	abstract[29]|abstract[30]	new[29]|new[30]	_	_
5-14	468-470	of	abstract[29]|abstract[30]	new[29]|new[30]	_	_
5-15	471-474	CRC	abstract[29]|abstract[30]|abstract	new[29]|new[30]|giv	coref	6-25
5-16	475-476	.	_	_	_	_

#Text=Over the last two decades , accumulating evidence has demonstrated that several members of the TRP family channels show altered expression and activity in cancer cells .
6-1	477-481	Over	_	_	_	_
6-2	482-485	the	time[32]	new[32]	_	_
6-3	486-490	last	time[32]	new[32]	_	_
6-4	491-494	two	time[32]	new[32]	_	_
6-5	495-502	decades	time[32]	new[32]	_	_
6-6	503-504	,	_	_	_	_
6-7	505-517	accumulating	_	_	_	_
6-8	518-526	evidence	abstract	new	_	_
6-9	527-530	has	_	_	_	_
6-10	531-543	demonstrated	_	_	_	_
6-11	544-548	that	_	_	_	_
6-12	549-556	several	person[34]	new[34]	_	_
6-13	557-564	members	person[34]	new[34]	_	_
6-14	565-567	of	person[34]	new[34]	_	_
6-15	568-571	the	person[34]|place[37]	new[34]|new[37]	coref	15-15[124_37]
6-16	572-575	TRP	person[34]|object|place[37]	new[34]|giv|new[37]	coref	15-17
6-17	576-582	family	person[34]|organization|place[37]	new[34]|new|new[37]	_	_
6-18	583-591	channels	person[34]|place[37]	new[34]|new[37]	_	_
6-19	592-596	show	_	_	_	_
6-20	597-604	altered	abstract[38]	new[38]	coref	7-3[43_38]
6-21	605-615	expression	abstract[38]	new[38]	_	_
6-22	616-619	and	_	_	_	_
6-23	620-628	activity	abstract[39]	new[39]	coref	9-1[63_39]
6-24	629-631	in	abstract[39]	new[39]	_	_
6-25	632-638	cancer	abstract[39]|abstract|object[41]	new[39]|giv|new[41]	coref|coref|coref|coref	7-15|13-19[109_41]|7-15|13-19[109_41]
6-26	639-644	cells	abstract[39]|object[41]	new[39]|new[41]	_	_
6-27	645-646	.	_	_	_	_

#Text=Levels of expression of TRPC , TRPM , and TRPV proteins depend on the cancer stage .
7-1	647-653	Levels	abstract[42]	new[42]	_	_
7-2	654-656	of	abstract[42]	new[42]	_	_
7-3	657-667	expression	abstract[42]|abstract[43]	new[42]|giv[43]	_	_
7-4	668-670	of	abstract[42]|abstract[43]	new[42]|giv[43]	_	_
7-5	671-675	TRPC	abstract[42]|abstract[43]|object	new[42]|giv[43]|new	_	_
7-6	676-677	,	abstract[42]|abstract[43]	new[42]|giv[43]	_	_
7-7	678-682	TRPM	abstract[42]|abstract[43]|abstract	new[42]|giv[43]|new	_	_
7-8	683-684	,	abstract[42]|abstract[43]	new[42]|giv[43]	_	_
7-9	685-688	and	abstract[42]|abstract[43]	new[42]|giv[43]	_	_
7-10	689-693	TRPV	abstract[42]|abstract[43]|abstract|substance[47]	new[42]|giv[43]|new|new[47]	_	_
7-11	694-702	proteins	abstract[42]|abstract[43]|substance[47]	new[42]|giv[43]|new[47]	_	_
7-12	703-709	depend	_	_	_	_
7-13	710-712	on	_	_	_	_
7-14	713-716	the	event[49]	new[49]	_	_
7-15	717-723	cancer	abstract|event[49]	giv|new[49]	coref	9-7
7-16	724-729	stage	event[49]	new[49]	_	_
7-17	730-731	.	_	_	_	_

#Text=Those differences have been recognized mainly in melanoma , glioma and prostate , breast , kidney , and bladder cancers , suggesting an oncogenic role for some TRPs while others may function as tumor suppressors .
8-1	732-737	Those	abstract[50]	new[50]	coref	15-28[128_50]
8-2	738-749	differences	abstract[50]	new[50]	_	_
8-3	750-754	have	_	_	_	_
8-4	755-759	been	_	_	_	_
8-5	760-770	recognized	_	_	_	_
8-6	771-777	mainly	_	_	_	_
8-7	778-780	in	_	_	_	_
8-8	781-789	melanoma	abstract	new	_	_
8-9	790-791	,	_	_	_	_
8-10	792-798	glioma	abstract	new	_	_
8-11	799-802	and	_	_	_	_
8-12	803-811	prostate	place	new	coref	17-27
8-13	812-813	,	_	_	_	_
8-14	814-820	breast	place	new	_	_
8-15	821-822	,	_	_	_	_
8-16	823-829	kidney	place	new	_	_
8-17	830-831	,	_	_	_	_
8-18	832-835	and	_	_	_	_
8-19	836-843	bladder	object|abstract[57]	new|giv[57]	_	_
8-20	844-851	cancers	abstract[57]	giv[57]	_	_
8-21	852-853	,	_	_	_	_
8-22	854-864	suggesting	_	_	_	_
8-23	865-867	an	abstract[58]	giv[58]	coref	12-5[92_58]
8-24	868-877	oncogenic	abstract[58]	giv[58]	_	_
8-25	878-882	role	abstract[58]	giv[58]	_	_
8-26	883-886	for	abstract[58]	giv[58]	_	_
8-27	887-891	some	abstract[58]|abstract[59]	giv[58]|new[59]	coref	9-1[0_59]
8-28	892-896	TRPs	abstract[58]|abstract[59]	giv[58]|new[59]	_	_
8-29	897-902	while	_	_	_	_
8-30	903-909	others	abstract	new	_	_
8-31	910-913	may	_	_	_	_
8-32	914-922	function	_	_	_	_
8-33	923-925	as	_	_	_	_
8-34	926-931	tumor	abstract	new	coref	9-18
8-35	932-943	suppressors	_	_	_	_
8-36	944-945	.	_	_	_	_

#Text=TRPs activity implicates many aspects of cancer development or “ hallmarks of cancer ” , such as tumor migration and invasion , exaggerated cell proliferation , cell survival , angiogenesis , and enhanced resistance to cell death .
9-1	946-950	TRPs	abstract|abstract[63]	giv|giv[63]	coref|coref	16-22[141_0]|16-22[141_0]
9-2	951-959	activity	abstract[63]	giv[63]	_	_
9-3	960-970	implicates	_	_	_	_
9-4	971-975	many	abstract[64]	new[64]	_	_
9-5	976-983	aspects	abstract[64]	new[64]	_	_
9-6	984-986	of	abstract[64]	new[64]	_	_
9-7	987-993	cancer	abstract[64]|abstract|event[66]	new[64]|giv|new[66]	coref|coref	9-13|9-13
9-8	994-1005	development	abstract[64]|event[66]	new[64]|new[66]	_	_
9-9	1006-1008	or	abstract[64]	new[64]	_	_
9-10	1009-1010	“	abstract[64]|abstract[67]	new[64]|new[67]	_	_
9-11	1011-1020	hallmarks	abstract[64]|abstract[67]	new[64]|new[67]	_	_
9-12	1021-1023	of	abstract[64]|abstract[67]	new[64]|new[67]	_	_
9-13	1024-1030	cancer	abstract[64]|abstract[67]|abstract	new[64]|new[67]|giv	coref	10-14
9-14	1031-1032	”	abstract[64]|abstract[67]	new[64]|new[67]	_	_
9-15	1033-1034	,	abstract[64]|abstract[67]	new[64]|new[67]	_	_
9-16	1035-1039	such	abstract[64]|abstract[67]	new[64]|new[67]	_	_
9-17	1040-1042	as	abstract[64]|abstract[67]	new[64]|new[67]	_	_
9-18	1043-1048	tumor	abstract[64]|abstract[67]|abstract|abstract[70]	new[64]|new[67]|giv|new[70]	_	_
9-19	1049-1058	migration	abstract[64]|abstract[67]|abstract[70]	new[64]|new[67]|new[70]	_	_
9-20	1059-1062	and	abstract[64]|abstract[67]	new[64]|new[67]	_	_
9-21	1063-1071	invasion	abstract[64]|abstract[67]|event	new[64]|new[67]|new	_	_
9-22	1072-1073	,	abstract[64]|abstract[67]	new[64]|new[67]	_	_
9-23	1074-1085	exaggerated	abstract[64]|abstract[67]|abstract[73]	new[64]|new[67]|new[73]	coref	14-23[117_73]
9-24	1086-1090	cell	abstract[64]|abstract[67]|place|abstract[73]	new[64]|new[67]|new|new[73]	coref	9-27
9-25	1091-1104	proliferation	abstract[64]|abstract[67]|abstract[73]	new[64]|new[67]|new[73]	_	_
9-26	1105-1106	,	abstract[64]|abstract[67]	new[64]|new[67]	_	_
9-27	1107-1111	cell	abstract[64]|abstract[67]|place|event[75]	new[64]|new[67]|giv|new[75]	coref|coref	9-36|9-36
9-28	1112-1120	survival	abstract[64]|abstract[67]|event[75]	new[64]|new[67]|new[75]	_	_
9-29	1121-1122	,	abstract[64]|abstract[67]	new[64]|new[67]	_	_
9-30	1123-1135	angiogenesis	abstract[64]|abstract[67]|abstract	new[64]|new[67]|new	_	_
9-31	1136-1137	,	abstract[64]|abstract[67]	new[64]|new[67]	_	_
9-32	1138-1141	and	abstract[64]|abstract[67]	new[64]|new[67]	_	_
9-33	1142-1150	enhanced	abstract[64]|abstract[67]|event[77]	new[64]|new[67]|new[77]	_	_
9-34	1151-1161	resistance	abstract[64]|abstract[67]|event[77]	new[64]|new[67]|new[77]	_	_
9-35	1162-1164	to	abstract[64]|abstract[67]|event[77]	new[64]|new[67]|new[77]	_	_
9-36	1165-1169	cell	abstract[64]|abstract[67]|event[77]|place|person[79]	new[64]|new[67]|new[77]|giv|giv[79]	coref|coref	14-14|14-14
9-37	1170-1175	death	abstract[64]|abstract[67]|event[77]|person[79]	new[64]|new[67]|new[77]|giv[79]	_	_
9-38	1176-1177	.	_	_	_	_

#Text=To date , TRPV1 and TRPV6 have been exclusively recognized as relevant in CRC carcinogenesis .
10-1	1178-1180	To	_	_	_	_
10-2	1181-1185	date	time	new	_	_
10-3	1186-1187	,	_	_	_	_
10-4	1188-1193	TRPV1	abstract	new	coref	11-6
10-5	1194-1197	and	_	_	_	_
10-6	1198-1203	TRPV6	abstract	new	coref	14-9
10-7	1204-1208	have	_	_	_	_
10-8	1209-1213	been	_	_	_	_
10-9	1214-1225	exclusively	_	_	_	_
10-10	1226-1236	recognized	_	_	_	_
10-11	1237-1239	as	_	_	_	_
10-12	1240-1248	relevant	_	_	_	_
10-13	1249-1251	in	_	_	_	_
10-14	1252-1255	CRC	abstract|abstract[84]	giv|new[84]	coref|coref	11-22|11-22
10-15	1256-1270	carcinogenesis	abstract[84]	new[84]	_	_
10-16	1271-1272	.	_	_	_	_

#Text=As mentioned above , the TRPV1 channel is also involved in IBD , a chronic disorder strongly correlated with risk of CRC .
11-1	1273-1275	As	_	_	_	_
11-2	1276-1285	mentioned	_	_	_	_
11-3	1286-1291	above	_	_	_	_
11-4	1292-1293	,	_	_	_	_
11-5	1294-1297	the	object[86]	new[86]	_	_
11-6	1298-1303	TRPV1	abstract|object[86]	giv|new[86]	coref	12-9[93_0]
11-7	1304-1311	channel	object[86]	new[86]	_	_
11-8	1312-1314	is	_	_	_	_
11-9	1315-1319	also	_	_	_	_
11-10	1320-1328	involved	_	_	_	_
11-11	1329-1331	in	_	_	_	_
11-12	1332-1335	IBD	event	new	_	_
11-13	1336-1337	,	_	_	_	_
11-14	1338-1339	a	abstract[88]	new[88]	_	_
11-15	1340-1347	chronic	abstract[88]	new[88]	_	_
11-16	1348-1356	disorder	abstract[88]	new[88]	_	_
11-17	1357-1365	strongly	_	_	_	_
11-18	1366-1376	correlated	_	_	_	_
11-19	1377-1381	with	_	_	_	_
11-20	1382-1386	risk	abstract[89]	new[89]	_	_
11-21	1387-1389	of	abstract[89]	new[89]	_	_
11-22	1390-1393	CRC	abstract[89]|abstract	new[89]|giv	coref	12-14[95_0]
11-23	1394-1395	.	_	_	_	_

#Text=Animal models have demonstrated a protective role for TRPV1 in the tumorigenesis of colon cancer , indeed TRPV1- Knockout mice exhibited lower expression of anti-inflammatory neuropeptides and greater occurrence and number of CRC compared with controls .
12-1	1396-1402	Animal	abstract[91]	new[91]	_	_
12-2	1403-1409	models	abstract[91]	new[91]	_	_
12-3	1410-1414	have	_	_	_	_
12-4	1415-1427	demonstrated	_	_	_	_
12-5	1428-1429	a	abstract[92]	giv[92]	_	_
12-6	1430-1440	protective	abstract[92]	giv[92]	_	_
12-7	1441-1445	role	abstract[92]	giv[92]	_	_
12-8	1446-1449	for	abstract[92]	giv[92]	_	_
12-9	1450-1455	TRPV1	abstract[92]|abstract[93]	giv[92]|giv[93]	coref	13-15[0_93]
12-10	1456-1458	in	abstract[92]|abstract[93]	giv[92]|giv[93]	_	_
12-11	1459-1462	the	abstract[92]|abstract[93]|event[94]	giv[92]|giv[93]|giv[94]	_	_
12-12	1463-1476	tumorigenesis	abstract[92]|abstract[93]|event[94]	giv[92]|giv[93]|giv[94]	_	_
12-13	1477-1479	of	abstract[92]|abstract[93]|event[94]	giv[92]|giv[93]|giv[94]	_	_
12-14	1480-1485	colon	abstract[92]|abstract[93]|event[94]|abstract[95]	giv[92]|giv[93]|giv[94]|giv[95]	coref	12-33[0_95]
12-15	1486-1492	cancer	abstract[92]|abstract[93]|event[94]|abstract[95]	giv[92]|giv[93]|giv[94]|giv[95]	_	_
12-16	1493-1494	,	_	_	_	_
12-17	1495-1501	indeed	_	_	_	_
12-18	1502-1508	TRPV1-	animal|animal[97]	new|new[97]	_	_
12-19	1509-1517	Knockout	animal[97]	new[97]	_	_
12-20	1518-1522	mice	animal[97]	new[97]	_	_
12-21	1523-1532	exhibited	_	_	_	_
12-22	1533-1538	lower	abstract[98]	new[98]	_	_
12-23	1539-1549	expression	abstract[98]	new[98]	_	_
12-24	1550-1552	of	abstract[98]	new[98]	_	_
12-25	1553-1570	anti-inflammatory	abstract[98]|object[99]	new[98]|new[99]	_	_
12-26	1571-1584	neuropeptides	abstract[98]|object[99]	new[98]|new[99]	_	_
12-27	1585-1588	and	abstract[98]	new[98]	_	_
12-28	1589-1596	greater	abstract[98]|abstract[100]	new[98]|new[100]	_	_
12-29	1597-1607	occurrence	abstract[98]|abstract[100]	new[98]|new[100]	_	_
12-30	1608-1611	and	abstract[98]	new[98]	_	_
12-31	1612-1618	number	abstract[98]|quantity[101]	new[98]|new[101]	_	_
12-32	1619-1621	of	abstract[98]|quantity[101]	new[98]|new[101]	_	_
12-33	1622-1625	CRC	abstract[98]|quantity[101]|abstract	new[98]|new[101]|giv	coref	14-13
12-34	1626-1634	compared	_	_	_	_
12-35	1635-1639	with	_	_	_	_
12-36	1640-1648	controls	event	new	_	_
12-37	1649-1650	.	_	_	_	_

#Text=In accordance with these data , Sung and colleagues demonstrated that agonist-mediated activation of TRPV1 induced apoptosis of CRC cells .
13-1	1651-1653	In	_	_	_	_
13-2	1654-1664	accordance	_	_	_	_
13-3	1665-1669	with	_	_	_	_
13-4	1670-1675	these	abstract[104]	new[104]	coref	17-1[145_104]
13-5	1676-1680	data	abstract[104]	new[104]	_	_
13-6	1681-1682	,	_	_	_	_
13-7	1683-1687	Sung	_	_	_	_
13-8	1688-1691	and	_	_	_	_
13-9	1692-1702	colleagues	person	new	_	_
13-10	1703-1715	demonstrated	_	_	_	_
13-11	1716-1720	that	abstract[106]	new[106]	_	_
13-12	1721-1737	agonist-mediated	abstract[106]	new[106]	_	_
13-13	1738-1748	activation	abstract[106]	new[106]	_	_
13-14	1749-1751	of	abstract[106]	new[106]	_	_
13-15	1752-1757	TRPV1	abstract[106]|object	new[106]|giv	coref	18-11
13-16	1758-1765	induced	abstract[106]|event[108]	new[106]|new[108]	_	_
13-17	1766-1775	apoptosis	abstract[106]|event[108]	new[106]|new[108]	_	_
13-18	1776-1778	of	abstract[106]|event[108]	new[106]|new[108]	_	_
13-19	1779-1782	CRC	abstract[106]|event[108]|object[109]	new[106]|new[108]|giv[109]	coref	14-27[118_109]
13-20	1783-1788	cells	abstract[106]|event[108]|object[109]	new[106]|new[108]|giv[109]	_	_
13-21	1789-1790	.	_	_	_	_

#Text=On the other hand , an overexpression of TRPV6 in SW480 colorectal cancer cell lines and colon carcinomas have been associated with an enhanced proliferation of malignant cells .
14-1	1791-1793	On	_	_	_	_
14-2	1794-1797	the	_	_	_	_
14-3	1798-1803	other	_	_	_	_
14-4	1804-1808	hand	_	_	_	_
14-5	1809-1810	,	_	_	_	_
14-6	1811-1813	an	abstract[110]	new[110]	_	_
14-7	1814-1828	overexpression	abstract[110]	new[110]	_	_
14-8	1829-1831	of	abstract[110]	new[110]	_	_
14-9	1832-1837	TRPV6	abstract[110]|abstract	new[110]|giv	coref	17-6
14-10	1838-1840	in	abstract[110]	new[110]	_	_
14-11	1841-1846	SW480	abstract[110]|object[114]	new[110]|new[114]	coref	16-11[139_114]
14-12	1847-1857	colorectal	abstract[110]|object[114]	new[110]|new[114]	_	_
14-13	1858-1864	cancer	abstract[110]|abstract|object[114]	new[110]|giv|new[114]	coref	15-40
14-14	1865-1869	cell	abstract[110]|place|object[114]	new[110]|giv|new[114]	_	_
14-15	1870-1875	lines	abstract[110]|object[114]	new[110]|new[114]	_	_
14-16	1876-1879	and	abstract[110]	new[110]	_	_
14-17	1880-1885	colon	abstract[110]|object|object[116]	new[110]|new|new[116]	coref|coref	16-12|16-12
14-18	1886-1896	carcinomas	abstract[110]|object[116]	new[110]|new[116]	_	_
14-19	1897-1901	have	_	_	_	_
14-20	1902-1906	been	_	_	_	_
14-21	1907-1917	associated	_	_	_	_
14-22	1918-1922	with	_	_	_	_
14-23	1923-1925	an	abstract[117]	giv[117]	_	_
14-24	1926-1934	enhanced	abstract[117]	giv[117]	_	_
14-25	1935-1948	proliferation	abstract[117]	giv[117]	_	_
14-26	1949-1951	of	abstract[117]	giv[117]	_	_
14-27	1952-1961	malignant	abstract[117]|object[118]	giv[117]|giv[118]	coref	16-6[136_118]
14-28	1962-1967	cells	abstract[117]|object[118]	giv[117]|giv[118]	_	_
14-29	1968-1969	.	_	_	_	_

#Text=In a recent report , Pérez-Riesgo et al. have assessed differential gene expression of all human TRP channels by Next Generation Sequencing ( NGS ) to investigate differences in expression of several genes involved in intracellular Ca2+ transport in CRC .
15-1	1970-1972	In	_	_	_	_
15-2	1973-1974	a	abstract[119]	new[119]	_	_
15-3	1975-1981	recent	abstract[119]	new[119]	_	_
15-4	1982-1988	report	abstract[119]	new[119]	_	_
15-5	1989-1990	,	_	_	_	_
15-6	1991-2003	Pérez-Riesgo	person	new	_	_
15-7	2004-2006	et	_	_	_	_
15-8	2007-2010	al.	_	_	_	_
15-9	2011-2015	have	_	_	_	_
15-10	2016-2024	assessed	_	_	_	_
15-11	2025-2037	differential	abstract[122]	new[122]	_	_
15-12	2038-2042	gene	abstract|abstract[122]	new|new[122]	coref	17-8[148_0]
15-13	2043-2053	expression	abstract[122]	new[122]	_	_
15-14	2054-2056	of	abstract[122]	new[122]	_	_
15-15	2057-2060	all	abstract[122]|place[124]	new[122]|giv[124]	coref	18-11[160_124]
15-16	2061-2066	human	abstract[122]|place[124]	new[122]|giv[124]	_	_
15-17	2067-2070	TRP	abstract[122]|object|place[124]	new[122]|giv|giv[124]	coref	17-10
15-18	2071-2079	channels	abstract[122]|place[124]	new[122]|giv[124]	_	_
15-19	2080-2082	by	abstract[122]|place[124]	new[122]|giv[124]	_	_
15-20	2083-2087	Next	abstract[122]|place[124]|abstract[125]|abstract[126]	new[122]|giv[124]|new[125]|new[126]	appos|appos	15-24[0_126]|15-24[0_126]
15-21	2088-2098	Generation	abstract[122]|place[124]|abstract[125]|abstract[126]	new[122]|giv[124]|new[125]|new[126]	_	_
15-22	2099-2109	Sequencing	abstract[122]|place[124]|abstract[126]	new[122]|giv[124]|new[126]	_	_
15-23	2110-2111	(	_	_	_	_
15-24	2112-2115	NGS	abstract	giv	_	_
15-25	2116-2117	)	_	_	_	_
15-26	2118-2120	to	_	_	_	_
15-27	2121-2132	investigate	_	_	_	_
15-28	2133-2144	differences	abstract[128]	giv[128]	_	_
15-29	2145-2147	in	abstract[128]	giv[128]	_	_
15-30	2148-2158	expression	abstract[128]|abstract[129]	giv[128]|new[129]	_	_
15-31	2159-2161	of	abstract[128]|abstract[129]	giv[128]|new[129]	_	_
15-32	2162-2169	several	abstract[128]|abstract[129]|abstract[130]	giv[128]|new[129]|new[130]	_	_
15-33	2170-2175	genes	abstract[128]|abstract[129]|abstract[130]	giv[128]|new[129]|new[130]	_	_
15-34	2176-2184	involved	_	_	_	_
15-35	2185-2187	in	_	_	_	_
15-36	2188-2201	intracellular	abstract[132]	new[132]	_	_
15-37	2202-2206	Ca2+	abstract|abstract[132]	new|new[132]	_	_
15-38	2207-2216	transport	abstract[132]	new[132]	_	_
15-39	2217-2219	in	abstract[132]	new[132]	_	_
15-40	2220-2223	CRC	abstract[132]|abstract	new[132]|giv	coref	16-13
15-41	2224-2225	.	_	_	_	_

#Text=The results obtained , comparing human normal colonic cells versus human colon cancer lines , revealed that only a dozen of the TRPs are expressed in colonic cells , either normal or tumor .
16-1	2226-2229	The	abstract[134]	new[134]	_	_
16-2	2230-2237	results	abstract[134]	new[134]	_	_
16-3	2238-2246	obtained	_	_	_	_
16-4	2247-2248	,	_	_	_	_
16-5	2249-2258	comparing	_	_	_	_
16-6	2259-2264	human	object[136]	giv[136]	coref	16-27[143_136]
16-7	2265-2271	normal	object[136]	giv[136]	_	_
16-8	2272-2279	colonic	abstract|object[136]	new|giv[136]	coref	16-27
16-9	2280-2285	cells	object[136]	giv[136]	_	_
16-10	2286-2292	versus	object[136]	giv[136]	_	_
16-11	2293-2298	human	object[136]|object[139]	giv[136]|giv[139]	_	_
16-12	2299-2304	colon	object[136]|object|object[139]	giv[136]|giv|giv[139]	_	_
16-13	2305-2311	cancer	object[136]|abstract|object[139]	giv[136]|giv|giv[139]	coref	17-15
16-14	2312-2317	lines	object[136]|object[139]	giv[136]|giv[139]	_	_
16-15	2318-2319	,	_	_	_	_
16-16	2320-2328	revealed	_	_	_	_
16-17	2329-2333	that	_	_	_	_
16-18	2334-2338	only	object[140]	new[140]	_	_
16-19	2339-2340	a	object[140]	new[140]	_	_
16-20	2341-2346	dozen	object[140]	new[140]	_	_
16-21	2347-2349	of	object[140]	new[140]	_	_
16-22	2350-2353	the	object[140]|abstract[141]	new[140]|giv[141]	_	_
16-23	2354-2358	TRPs	object[140]|abstract[141]	new[140]|giv[141]	_	_
16-24	2359-2362	are	_	_	_	_
16-25	2363-2372	expressed	_	_	_	_
16-26	2373-2375	in	_	_	_	_
16-27	2376-2383	colonic	abstract|object[143]	giv|giv[143]	appos|appos	16-33[0_143]|16-33[0_143]
16-28	2384-2389	cells	object[143]	giv[143]	_	_
16-29	2390-2391	,	_	_	_	_
16-30	2392-2398	either	_	_	_	_
16-31	2399-2405	normal	_	_	_	_
16-32	2406-2408	or	_	_	_	_
16-33	2409-2414	tumor	object	giv	coref	17-15[150_0]
16-34	2415-2416	.	_	_	_	_

#Text=The data also indicated that TRPV6 was the unique TRP gene significantly overexpressed in CRC cells , resembling the previously reported enhanced levels of TRPV6 in prostate cancer .
17-1	2417-2420	The	abstract[145]	giv[145]	_	_
17-2	2421-2425	data	abstract[145]	giv[145]	_	_
17-3	2426-2430	also	_	_	_	_
17-4	2431-2440	indicated	_	_	_	_
17-5	2441-2445	that	_	_	_	_
17-6	2446-2451	TRPV6	abstract	giv	coref	17-25[152_0]
17-7	2452-2455	was	_	_	_	_
17-8	2456-2459	the	abstract[148]	giv[148]	_	_
17-9	2460-2466	unique	abstract[148]	giv[148]	_	_
17-10	2467-2470	TRP	person|abstract[148]	giv|giv[148]	_	_
17-11	2471-2475	gene	abstract[148]	giv[148]	_	_
17-12	2476-2489	significantly	_	_	_	_
17-13	2490-2503	overexpressed	_	_	_	_
17-14	2504-2506	in	_	_	_	_
17-15	2507-2510	CRC	substance|object[150]	giv|giv[150]	coref|coref	17-27[154_0]|17-27[154_0]
17-16	2511-2516	cells	object[150]	giv[150]	_	_
17-17	2517-2518	,	_	_	_	_
17-18	2519-2529	resembling	_	_	_	_
17-19	2530-2533	the	abstract[151]	new[151]	_	_
17-20	2534-2544	previously	abstract[151]	new[151]	_	_
17-21	2545-2553	reported	abstract[151]	new[151]	_	_
17-22	2554-2562	enhanced	abstract[151]	new[151]	_	_
17-23	2563-2569	levels	abstract[151]	new[151]	_	_
17-24	2570-2572	of	abstract[151]	new[151]	_	_
17-25	2573-2578	TRPV6	abstract[151]|abstract[152]	new[151]|giv[152]	coref	18-13[0_152]
17-26	2579-2581	in	abstract[151]|abstract[152]	new[151]|giv[152]	_	_
17-27	2582-2590	prostate	abstract[151]|abstract[152]|place|abstract[154]	new[151]|giv[152]|giv|giv[154]	coref|coref	18-16[0_154]|18-16[0_154]
17-28	2591-2597	cancer	abstract[151]|abstract[152]|abstract[154]	new[151]|giv[152]|giv[154]	_	_
17-29	2598-2599	.	_	_	_	_

#Text=Notwithstanding , the functional consequences of changes in expression of TRPV1 and TRPV6 channels in CRC remain to be established .
18-1	2600-2615	Notwithstanding	_	_	_	_
18-2	2616-2617	,	_	_	_	_
18-3	2618-2621	the	abstract[155]	new[155]	_	_
18-4	2622-2632	functional	abstract[155]	new[155]	_	_
18-5	2633-2645	consequences	abstract[155]	new[155]	_	_
18-6	2646-2648	of	abstract[155]	new[155]	_	_
18-7	2649-2656	changes	abstract[155]|abstract	new[155]|new	_	_
18-8	2657-2659	in	abstract[155]	new[155]	_	_
18-9	2660-2670	expression	abstract[155]|abstract[157]	new[155]|new[157]	_	_
18-10	2671-2673	of	abstract[155]|abstract[157]	new[155]|new[157]	_	_
18-11	2674-2679	TRPV1	abstract[155]|abstract[157]|object|place[160]	new[155]|new[157]|giv|giv[160]	_	_
18-12	2680-2683	and	abstract[155]|abstract[157]|place[160]	new[155]|new[157]|giv[160]	_	_
18-13	2684-2689	TRPV6	abstract[155]|abstract[157]|object|place[160]	new[155]|new[157]|giv|giv[160]	_	_
18-14	2690-2698	channels	abstract[155]|abstract[157]|place[160]	new[155]|new[157]|giv[160]	_	_
18-15	2699-2701	in	abstract[155]|abstract[157]|place[160]	new[155]|new[157]|giv[160]	_	_
18-16	2702-2705	CRC	abstract[155]|abstract[157]|place[160]|object	new[155]|new[157]|giv[160]|giv	_	_
18-17	2706-2712	remain	_	_	_	_
18-18	2713-2715	to	_	_	_	_
18-19	2716-2718	be	_	_	_	_
18-20	2719-2730	established	_	_	_	_
18-21	2731-2732	.	_	_	_	_
